BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient's physician. The Company's multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient's specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Home Health Care
- Sub-Industry: Health Care Services
- Exchange: NASDAQ
- Symbol: BIOS
- CUSIP: 09069N10
- Previous Close: $1.58
- 50 Day Moving Average: $1.53
- 200 Day Moving Average: $2.04
- 52-Week Range: $117,682,000.00 - $0.98
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.75
- P/E Growth: -0.33
- Market Cap: $183.58M
- Outstanding Shares: 117,682,000
- Beta: 0.6
- Net Margins: -5.18%
- Return on Assets: -5.82%
Companies Related to BioScrip:
- Debt-to-Equity Ratio: -15.98%
- Current Ratio: 1.13%
- Quick Ratio: 0.89%
What is BioScrip's stock symbol?
BioScrip trades on the NASDAQ under the ticker symbol "BIOS."
Where is BioScrip's stock going? Where will BioScrip's stock price be in 2017?
3 brokers have issued 1-year price targets for BioScrip's shares. Their forecasts range from $2.50 to $4.50. On average, they expect BioScrip's stock price to reach $3.50 in the next twelve months.
When will BioScrip announce their earnings?
BioScrip is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
Who owns BioScrip stock?
BioScrip's stock is owned by a variety of of retail and institutional investors. Top institutional investors include
GAMCO INVESTORS, INC. ET AL
(14.26%), Gabelli Funds LLC (12.75%), Wynnefield Capital Inc. (3.14%), FMR LLC (3.00%), Deerfield Management Co. (1.68%) and Dimensional Fund Advisors LP (1.36%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, R Carter Pate, Richard M Smith and Yon Jorden.
Who sold BioScrip stock? Who is selling BioScrip stock?
BioScrip's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Menta Capital LLC and Formidable Asset Management LLC.
Who bought BioScrip stock? Who is buying BioScrip stock?
BioScrip's stock was purchased by a variety of institutional investors in the last quarter, including Wynnefield Capital Inc., FMR LLC, Gabelli Funds LLC, Gamco Investors INC. ET AL, State Street Corp and Teton Advisors Inc.. Company insiders that have bought BioScrip stock in the last two years include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, R Carter Pate, Richard M Smith and Yon Jorden.
How do I buy BioScrip stock?
Shares of BioScrip can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of BioScrip stock cost?
One share of BioScrip stock can currently be purchased for approximately $1.56.